Please assess the completion status of the following clinical trial:

Trial Title: Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed locally advanced/metastatic (stage IIIB/stage IV, using the American Joint Committee on Cancer \[AJCC\] 6th edition of tumor-node-metastasis \[TNM\] staging system) NSCLC patients~* Progressed after at least one platinum-based chemotherapy regimen at entry~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~* At least one measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.0~* Adequate hematologic and biochemical values~Exclusion Criteria:~* Patients with symptomatic brain metastases~* Malignant tumor within the previous five years~* Severe infection; congestive heart failure~* Previous treatment with drugs targeting EGFR~* History of interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- icotinib (Type: EXPERIMENTAL): Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).